- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07631689
Effect of Discarding Initial Reperfusion Blood on Hemodynamics, Liver Function, and 30-Day Outcomes in Liver Transplantation
Assessment of the Impact of Discarding the Initial Reperfusion Blood on Early Liver Function, Cardiovascular and Metabolic Changes and on 30-Day Liver and Renal Outcomes. A Prospective Randomized Trial in Liver Transplantation
Hepatic reperfusion during liver transplantation remains a critical phase associated with significant hemodynamic and systemic disturbances, despite advances in surgical and anesthetic management. This phase is characterized by the release of acidotic, hypothermic, and hyperkalemic blood containing metabolic byproducts and inflammatory mediators resulting from ischemia-reperfusion injury.
Clinically, reperfusion is associated with hemodynamic instability, including reductions in cardiac output and arterial pressure, as well as cardiac dysfunction and arrhythmias, often requiring pharmacologic support. These alterations may affect not only immediate intraoperative stability but also short- and long-term outcomes for both the patient and the graft.
The abrupt restoration of blood flow to the transplanted liver leads to the systemic release of accumulated metabolites, reactive oxygen species, and inflammatory mediators, contributing to a systemic inflammatory response that may impact distant organs, including the kidneys and heart.
Several revascularization strategies have been investigated to mitigate reperfusion-related injury: initial reperfusion via the portal vein, initial reperfusion through the hepatic artery, and simultaneous reperfusion through the portal vein and hepatic artery.
A less frequently used and insufficiently studied strategy, not routinely or systematically implemented, involves diverting the initial reperfusion blood from the graft to the surgical field, followed by the restoration of hepatic blood outflow to the systemic circulation.
This study hypothesizes that discarding the initial reperfusion blood via the infrahepatic vena cava will attenuate early hemodynamic, metabolic, and inflammatory changes and reduce postoperative complications compared to conventional reperfusion techniques.
Przegląd badań
Status
Interwencja / Leczenie
Szczegółowy opis
Hepatic reperfusion during liver transplantation remains a critical phase associated with significant hemodynamic and systemic disturbances, despite advances in surgical and anesthetic management. This phase is characterized by the release of acidotic, hypothermic, and hyperkalemic blood containing metabolic byproducts and inflammatory mediators resulting from ischemia-reperfusion injury.
Clinically, reperfusion is associated with hemodynamic instability, including reductions in cardiac output and arterial pressure, as well as cardiac dysfunction and arrhythmias, often requiring pharmacologic support. These alterations may compromise immediate intraoperative stability and have been associated with adverse short- and long-term outcomes for both the recipient and the graft.
The abrupt restoration of blood flow to the transplanted liver results in the systemic release of accumulated metabolites, reactive oxygen species, and inflammatory mediators, triggering a systemic inflammatory response that may extend beyond the liver and affect distant organs, including the kidneys and heart.
Several revascularization strategies have been investigated to mitigate reperfusion-related injury, including portal vein, hepatic artery, and simultaneous reperfusion approaches. However, none have consistently demonstrated a clear benefit in reducing ischemia-reperfusion injury or improving clinical outcomes. An alternative and less explored strategy involves diverting and discarding the initial reperfusion blood from the graft before restoring venous outflow to the systemic circulation.
Patients listed for liver transplantation at the study center will be systematically screened for eligibility. Written informed consent will be obtained from all eligible participants prior to enrollment, in accordance with institutional ethical standards.
This study is a prospective randomized clinical trial designed to evaluate whether discarding the initial reperfusion blood via the infrahepatic vena cava attenuates early hemodynamic, metabolic, and inflammatory disturbances and improves postoperative outcomes compared with conventional reperfusion techniques.
Typ studiów
Zapisy (Szacowany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Joel Avancini Rocha Filho, MD, PhD
- Numer telefonu: +55 11 981422500
- E-mail: joel.rocha@hc.fm.usp.br
Kopia zapasowa kontaktu do badania
- Nazwa: Estela Regina Ramos Figueira, MD, PhD
- Numer telefonu: +55 11 999454871
- E-mail: estela.figueira@hc.fm.usp.br
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Opis
Inclusion Criteria:
- Adults aged 18 years or older
- Candidates for liver transplantation at Hospital das Clínicas, University of São Paulo Medical School (HCFMUSP)
- Able to provide written informed consent
Exclusion Criteria:
- Inability to provide informed consent
- Previous liver surgery
- Fulminant hepatitis
- Specific liver diseases associated with severe electrolyte disturbances
- End-stage renal disease requiring dialysis
- Combined organ transplantation
- Living donor liver transplantation
- Liver retransplantation
- Highly sensitized patients with limited availability of blood products
- Hematologic diseases
- Portal vein thrombosis involving more than 50% of the lumen
- Portopulmonary hypertension (mean pulmonary artery pressure > 20 mmHg), diagnosed preoperatively or intraoperatively
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Reperfusion Blood Discard
Liver transplantation with discarding of the initial 180 mL of reperfusion blood via the infrahepatic vena cava prior to restoration of hepatic blood outflow to the systemic circulation
|
Discarding of the initial 180 mL of reperfusion blood from the graft via the infrahepatic vena cava during liver transplantation prior to restoration of hepatic venous outflow to systemic circulation.
|
|
Aktywny komparator: Conventional Reperfusion
Standard liver transplantation without discarding the initial reperfusion blood.
|
Conventional liver transplantation without discarding the initial reperfusion blood.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Peak alanine aminotransferase (ALT)
Ramy czasowe: Within 72 hours after transplantation
|
Peak serum ALT level (U/L) as a biomarker of early graft injury following liver transplantation.
|
Within 72 hours after transplantation
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Arterial Pressure
Ramy czasowe: Intraoperative, during reperfussion, 30 minutes after reperfusion, and postoperative day 1.
|
Monitoring arterial pressure (systolic, diastolic e medium) Unit of Measure: mmHg.
|
Intraoperative, during reperfussion, 30 minutes after reperfusion, and postoperative day 1.
|
|
Cardiac Rhythm
Ramy czasowe: Intraoperative, during reperfussion, 30 minutes after reperfusion, and postoperative day 1
|
Cardiac rhythm monitoring with electrocardiography in ECG lead 2 and V5
|
Intraoperative, during reperfussion, 30 minutes after reperfusion, and postoperative day 1
|
|
Cardiac Output
Ramy czasowe: Intraoperative, during reperfussion, 30 minutes after reperfusion, and postoperative day 1.
|
Monitoring continuous cardiac output.
Unit of Measure: L/min.
|
Intraoperative, during reperfussion, 30 minutes after reperfusion, and postoperative day 1.
|
|
Arterial serum potassium levels
Ramy czasowe: Intraoperative and daily from postoperative day 1 up to day 7.
|
Perioperative changes in arterial potassium levels (Unit of measure: mEq/L).
|
Intraoperative and daily from postoperative day 1 up to day 7.
|
|
Blood coagulation thromboelastometry
Ramy czasowe: Intraoperative (at the start of surgery, 5 minutes after reperfusion, and at the end of surgery).
|
Assessment of intraoperative coagulation changes using rotational thromboelastometry (ROTEM), including EXTEM and FIBTEM parameters, and activated clotting time (ACT).
|
Intraoperative (at the start of surgery, 5 minutes after reperfusion, and at the end of surgery).
|
|
International normalized ratio (INR)
Ramy czasowe: Daily up to 72 hours after transplantation.
|
Assessment of graft function using international normalized ratio (INR).
|
Daily up to 72 hours after transplantation.
|
|
Aspartate aminotransferase levels (AST)
Ramy czasowe: Daily up to 7 days and weekly up to 30 days after transplantation.
|
Assessment of graft injury using serum levels of AST (Unit of measure: U/L).
|
Daily up to 7 days and weekly up to 30 days after transplantation.
|
|
Serum Tumor Necrosis Factor-alpha (TNF-α)
Ramy czasowe: At the start of surgery, end of surgery, postoperative day 1, and postoperative day 3.
|
Serum levels of inflammatory mediator TNF-α (Unit of measure: pg/mL).
|
At the start of surgery, end of surgery, postoperative day 1, and postoperative day 3.
|
|
Serum B-type natriuretic peptide (BNP)
Ramy czasowe: At the start of surgery, 30 minutes after reperfusion and postoperative day 1.
|
Assessment of BNP levels as a marker of cardiac hemodynamic stress.
Unit of Measure: pg/mL.
|
At the start of surgery, 30 minutes after reperfusion and postoperative day 1.
|
|
Serum creatinine levels
Ramy czasowe: Up to 30 days after transplantation.
|
Assessment of serum creatinine levels to evaluate renal function (Unit of measure: mg/dL),
|
Up to 30 days after transplantation.
|
|
Postoperative complications
Ramy czasowe: Within 30 days after transplantation.
|
Complications graded according to the Clavien-Dindo classification.
|
Within 30 days after transplantation.
|
|
ICU length of stay
Ramy czasowe: Up to 30 days after transplantation.
|
Days of length of stay in the intensive care unit.
|
Up to 30 days after transplantation.
|
|
Hospital length of stay
Ramy czasowe: Up to 30 days after transplantation.
|
Total hospital length of stay in days.
|
Up to 30 days after transplantation.
|
|
Arterial serum sodium levels
Ramy czasowe: Intraoperative and daily from postoperative day 1 up to day 7.
|
Perioperative changes in arterial serum sodium levels (Unit of measure: mEq/L).
|
Intraoperative and daily from postoperative day 1 up to day 7.
|
|
Arterial serum lactate levels
Ramy czasowe: Intraoperative and daily from postoperative day 1 up to day 7.
|
Perioperative changes in arterial serum lactate levels (Unit of measure mg/dL),
|
Intraoperative and daily from postoperative day 1 up to day 7.
|
|
Arterial serum calcium levels
Ramy czasowe: Intraoperative and daily from postoperative day 1 up to day 7.
|
Perioperative changes in arterial serum calcium levels (Unit of measure mg/dL),
|
Intraoperative and daily from postoperative day 1 up to day 7.
|
|
Serum glucose levels
Ramy czasowe: Intraoperative and daily from postoperative day 1 up to day 7.
|
Perioperative changes in serum glucose levels (Unit of measure: mg/dL).
|
Intraoperative and daily from postoperative day 1 up to day 7.
|
|
Arterial serum pH
Ramy czasowe: Intraoperative and daily from postoperative day 1 up to day 7.
|
Perioperative changes in arterial pH units.
|
Intraoperative and daily from postoperative day 1 up to day 7.
|
|
Arterial serum bicarbonate
Ramy czasowe: Intraoperative and daily from postoperative day 1 up to day 7.
|
Perioperative changes in arterial serum bicarbonate (Unit of measure mmol/L)
|
Intraoperative and daily from postoperative day 1 up to day 7.
|
|
Factor V activity levels
Ramy czasowe: Daily up to 72 hours after transplantation .
|
Assessment of graft function using Factor V activity levels measure as percentage.
|
Daily up to 72 hours after transplantation .
|
|
Alkaline phosphatase levels
Ramy czasowe: Daily up to 7 days and weekly up to 30 days after transplantation.
|
Assessement of graft function using alkaline phosphatase levels (Unit of measure: U/L),
|
Daily up to 7 days and weekly up to 30 days after transplantation.
|
|
Gamma-glutamyl transferase levels
Ramy czasowe: Daily up to 7 days and weekly up to 30 days after transplantation.
|
Assessment of liver function using serum levels of gamma-glutamyl transferase up to 7 days and weekly up to 30 days after transplantation (Unit of measure: U/L).
|
Daily up to 7 days and weekly up to 30 days after transplantation.
|
|
Serum ammonia levels
Ramy czasowe: Daily up to 7 days and weekly up to 30 days after transplantation.
|
Assessment of serum ammonia levels to evaluate liver function.(Unit of measure: mcmol/L).
|
Daily up to 7 days and weekly up to 30 days after transplantation.
|
|
Serum urea levels
Ramy czasowe: Up to 30 days after transplantation.
|
Assessment of serum urea levels to evaluate renal function (Unit of measure: mg/dl),
|
Up to 30 days after transplantation.
|
|
Urine output
Ramy czasowe: Up to 30 days after transplantation.
|
Assessment of renal function measured by daily urine output.
|
Up to 30 days after transplantation.
|
|
Need for renal replacement therapy
Ramy czasowe: Up to 30 days after transplantation.
|
Need for renal replacement therapy (hemodialysis or continuous renal replacement therapy).
|
Up to 30 days after transplantation.
|
|
Serum Interleukin-6 (IL-6) levels
Ramy czasowe: At the start of surgery, end of surgery, postoperative day 1, and postoperative day 3.
|
Serum levels of inflammatory mediator IL-6 (Unit of measure: pg/mL),
|
At the start of surgery, end of surgery, postoperative day 1, and postoperative day 3.
|
|
Serum Tumor Necrosis Factor-alpha (TNF-α) levels
Ramy czasowe: At the start of surgery, end of surgery, postoperative day 1, and postoperative day 3.
|
Serum levels of inflammatory mediator TNF-α levels.
(Unit of measure: pg/mL)
|
At the start of surgery, end of surgery, postoperative day 1, and postoperative day 3.
|
|
Serum Interleukin-17 (IL-17) levels
Ramy czasowe: At the start of surgery, end of surgery, postoperative day 1, and postoperative day 3.
|
Serum levels of inflammatory mediator IL-17 (Unit of measure: pg/mL).
|
At the start of surgery, end of surgery, postoperative day 1, and postoperative day 3.
|
Współpracownicy i badacze
Śledczy
- Główny śledczy: Joel Avancini Rocha Filho, MD, PhD, Hospital das Clínicas, University of São Paulo Medical School
- Dyrektor Studium: Estela Regina Ramos Figueira, MD, PhD, Hospital das Clínicas, University of São Paulo Medical School
- Dyrektor Studium: Maria Jose Carvalho Carmona, MD, PhD, Hospital das Clínicas, University of São Paulo Medical School
- Dyrektor Studium: Wellington Andraus, MD, PhD, Hospital das Clínicas, University of São Paulo Medical School
- Dyrektor Studium: Rui Carlos Detsch Junior, MD, Hospital das Clínicas, University of São Paulo Medical School
- Dyrektor Studium: Luciana Bertocco Paiva Haddad, MD, PhD, Hospital das Clínicas, University of São Paulo Medical School
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 92854125.8.0000.0068
- 2025/09932-0 (Inny numer grantu/finansowania: São Paulo Research Foundation (FAPESP))
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Transplantacja wątroby
-
University Hospital, Basel, SwitzerlandJeszcze nie rekrutacjaZespół sercowo-naczyniowy-kidney-metaboliczny | Zespół CradiovaCular-Kidney-Liver-Metabolic (CKLM)Szwajcaria
Badania kliniczne na Reperfusion Blood Discard
-
Nanjing Medical UniversityJeszcze nie rekrutacjaRak płaskonabłonkowy przełyku
-
Beijing GoBroad HospitalRekrutacyjnyTwardzina układowa | Oporne na leczenie toczniowe zapalenie nerek | Zespół pierwotnego Sjogrena w połączeniu z nadciśnieniem płucnymChiny
-
Ischemia Care LLCZakończonyUdar niedokrwienny | Migotanie przedsionków | Udar zakrzepowy | Przejściowe ataki niedokrwienne | Udar sercowo-zatorowy | Udar tętnicy podstawnej | Przejściowe zdarzenia naczyniowo-mózgoweStany Zjednoczone
-
Applied Science & Performance InstituteZakończonyNiedobór żelaza (bez niedokrwistości)Stany Zjednoczone
-
George Fox UniversityNieznanySłabe mięśnie | Czy terapia ograniczająca przepływ krwi zwiększa wzrost siły w mankiecie rotatorówStany Zjednoczone
-
Christopher BellZakończonyĆwiczenie wytrzymałościoweStany Zjednoczone
-
University of Maryland, BaltimoreZakończonyNie-anemiczny niedobór żelazaStany Zjednoczone
-
Reham HassanZakończonyWpływ elementówEgipt
-
University Hospital, Clermont-FerrandCentre Jean PerrinNieznanyKwantyfikacja spoczynku/stresu dyssynchronii lewej komory za pomocą bramkowanej puli krwi 3D D-SPECTDyssynchronia lewej komoryFrancja
-
Changi General HospitalZakończonyKrwotok | Powikłania związane z cewnikiem | Dializa; Komplikacje | Powikłanie rany | Krwawiąca RanaSingapur